QVAR®: Daily Asthma Treatment
Asthma may be a chronic persistent condition. That means that, even on days you aren't feeling asthma symptoms like coughing or trouble breathing, you still need to treat the underlying airway inflammation that causes your asthma symptoms. If you don't control your asthma, it can lead to more severe symptoms, poor quality of life, and even a greater risk of needing to go to the emergency room.1
QVAR®, a controller medication for asthma, can help reduce persistent asthma symptoms. The QVAR® inhaler is designed for everyday use, delivering a consistent dose of medication to the airways in your lungs.2,3
And with QVAR®, more of the medicine ends up in your lungs, where it's needed, and less in your mouth and throat.3-5 This may be due to the fact that QVAR® is a small-particle corticosteroid— QVAR® reaches the small airways in your lungs becauses of its small particle size.6,7
(beclomethasone dipropionate HFA) Inhalation Aerosol is used in the ongoing treatment of asthma as preventative therapy in patients 5 years of age or older.
is also used for asthma patients who require systemic corticosteroid administration, where adding QVAR®
may reduce or eliminate the need for systemic corticosteroids.
does not replace quick-relief inhalers for sudden symptoms.
CAUTION: If you are stopping or switching from an oral corticosteroid to QVAR®, follow your doctor's instructions to avoid health risks. (See WARNINGS, Prescribing Information).
Inhaled corticosteroids may cause a reduction in growth rate, so children taking QVAR®
should have their growth checked regularly. The long-term effect on final adult growth is unknown.
Do not stop taking QVAR®
abruptly without talking to your doctor.
In clinical studies, common side effects included headache and sore throat. These are not all of the possible side effects of QVAR®
. For more information, ask your healthcare provider or pharmacist.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch
, or call 1-800-FDA-1088
- NHLBI Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Accessed April 20, 2010.
- Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med. 2000;94(suppl B):S3-S9.
- Vanden Burgt J, Busse WW, Martin RJ, Szefler SJ, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane beclomethasone extra fine inhalation aerosol) in asthma. J Allergy Clin Immunol. 2000;106:1209-1224.
- Leach CL, Kuehl PJ, Chand R, Ketai L, Norenberg JP, McDonald JD. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol. 2012;108(3)195-200.
- DOF: Data on file. Teva Respiratory, LLC; 2010.
- Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122:510-516.
- Leach CL. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104:S250-S252.